公开(公告)号：JP2002234899A

公开(公告)日：2002-08-23

申请号：JP2001395485

申请日：2001-12-26

Applicant: COR THERAPEUTICS INC

Inventor： DAVID WOLF

IPC: C12N15/09 ,  A61K38/43 ,  A61P7/00 ,  A61P9/08 ,  A61P9/10 ,  C07K14/745

Abstract: PROBLEM TO BE SOLVED: To provide another method that increases the specificity of blocking the formation of active prothrombinase complex and can prolong the duration time of this action. SOLUTION: The objective medicine is the factor Xa of the blood factor that is modified so that the half-life may be transitorily prolonged in the serum and the modified blood factor gives the activated form of the blood factor in the presence of serum. The factor Xa that is the blood factor modified so that the half-life thereof may be prolonged in the serum is mixed with a pharmaceutically acceptable excipient and is used for treating hemophilia wherein the activated form of the blood factor is produced in the presence of serum.

公开(公告)号：AU3236493A

公开(公告)日：1993-06-28

申请号：AU3236493

申请日：1992-12-01

Applicant: COR THERAPEUTICS INC

Inventor： DAVID WOLF ,  JAMES E TOMLINSON

IPC: C12N5/00 ,  A61K38/00 ,  C07K14/71 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/27 ,  C12P21/00 ,  C12P21/02 ,  C12R1/91

Abstract: Cell lines and methods for high efficiency production of soluble peptides having platelet-derived growth factor (PDGF) ligand binding activity. Cell lines are provided which secrete soluble fragments from extracellular regions of PDGF receptor (PDGF-R) polypeptides. Methods using these cell lines for production of the fragments are also provided.